PLSH (Panacea Life Sciences Holdings) Piotroski F-Score: 4 (As of Jun. 24, 2026) — Near Median


What is Panacea Life Sciences Holdings Piotroski F-Score?

Panacea Life Sciences Holdings PLSH +3.64% Piotroski F-Score is 4 as of Jun. 24, 2026, which is at its 10-year median of 4.00. The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks worse than 60.86% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Panacea Life Sciences Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Panacea Life Sciences Holdings's Piotroski F-Score or its related term are showing as below:

PLSH' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 4

During the past 4 years, the highest Piotroski F-Score of Panacea Life Sciences Holdings was 5. The lowest was 2. And the median was 4.

Panacea Life Sciences Holdings  (OTCPK:PLSH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Panacea Life Sciences Holdings Piotroski F-Score Related Terms


Panacea Life Sciences Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Panacea Life Sciences Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Life Sciences Holdings Piotroski F-Score Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 2.00 3.00

Panacea Life Sciences Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 5.00 4.00

PLSH vs NPHC, OWPC, CBDY: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Life Sciences Holdings Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep25) TTM:Last Year (Jun24) TTM:
Net Income was -1.129 + -0.003 + 0.973 + -0.184 = $-0.34 Mil.
Cash Flow from Operations was -0.198 + 0.525 + -0.495 + -1.456 = $-1.62 Mil.
Revenue was 0.949 + 0.596 + 0.215 + 0.05 = $1.81 Mil.
Gross Profit was 0.729 + 0.278 + 0.184 + 0.047 = $1.24 Mil.
Average Total Assets from the begining of this year (Jun24)
to the end of this year (Sep25) was
(17.006 + 16.359 + 8.824 + 6.826 + 3.984) / 5 = $10.5998 Mil.
Total Assets at the begining of this year (Jun24) was $17.01 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $3.69 Mil.
Total Current Liabilities was $0.23 Mil.
Net Income was -2.151 + -2.209 + -1.446 + -1.462 = $-7.27 Mil.

Revenue was 0.348 + 0.96 + 1.054 + 1.174 = $3.54 Mil.
Gross Profit was 0.147 + 0.547 + 0.666 + 0.721 = $2.08 Mil.
Average Total Assets from the begining of last year (Jun23)
to the end of last year (Jun24) was
(17.854 + 18.733 + 17.983 + 17.413 + 17.006) / 5 = $17.7978 Mil.
Total Assets at the begining of last year (Jun23) was $17.85 Mil.
Long-Term Debt & Capital Lease Obligation was $6.71 Mil.
Total Current Assets was $4.89 Mil.
Total Current Liabilities was $21.38 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Panacea Life Sciences Holdings's current Net Income (TTM) was -0.34. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Panacea Life Sciences Holdings's current Cash Flow from Operations (TTM) was -1.62. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun24)
=-0.343/17.006
=-0.02016935

ROA (Last Year)=Net Income/Total Assets (Jun23)
=-7.268/17.854
=-0.40707965

Panacea Life Sciences Holdings's return on assets of this year was -0.02016935. Panacea Life Sciences Holdings's return on assets of last year was -0.40707965. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Panacea Life Sciences Holdings's current Net Income (TTM) was -0.34. Panacea Life Sciences Holdings's current Cash Flow from Operations (TTM) was -1.62. ==> -1.62 <= -0.34 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Sep25
=0/10.5998
=0

Gearing (Last Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=6.709/17.7978
=0.3769567

Panacea Life Sciences Holdings's gearing of this year was 0. Panacea Life Sciences Holdings's gearing of last year was 0.3769567. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep25)=Total Current Assets/Total Current Liabilities
=3.686/0.234
=15.75213675

Current Ratio (Last Year: Jun24)=Total Current Assets/Total Current Liabilities
=4.893/21.381
=0.22884804

Panacea Life Sciences Holdings's current ratio of this year was 15.75213675. Panacea Life Sciences Holdings's current ratio of last year was 0.22884804. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Panacea Life Sciences Holdings's number of shares in issue this year was 42.166. Panacea Life Sciences Holdings's number of shares in issue last year was 16.493. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.238/1.81
=0.6839779

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.081/3.536
=0.5885181

Panacea Life Sciences Holdings's gross margin of this year was 0.6839779. Panacea Life Sciences Holdings's gross margin of last year was 0.5885181. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun24)
=1.81/17.006
=0.10643302

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun23)
=3.536/17.854
=0.19805086

Panacea Life Sciences Holdings's asset turnover of this year was 0.10643302. Panacea Life Sciences Holdings's asset turnover of last year was 0.19805086. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+1+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Panacea Life Sciences Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Panacea Life Sciences Holdings (PLSH) has a Piotroski F-Score of 4 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Panacea Life Sciences Holdings and its competitors. This is near median its historical median of 4.00. Over the past decade, Panacea Life Sciences Holdings' Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #597 out of 981 companies in the Drug Manufacturers industry, placing it in the top 60.9%.
Is Panacea Life Sciences Holdings' Piotroski F-Score too high?
Panacea Life Sciences Holdings' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Panacea Life Sciences Holdings' value of 4 is 20% below this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #597 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Panacea Life Sciences Holdings' Piotroski F-Score compare to NPHC and OWPC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #597 out of 981 companies for Piotroski F-Score. This places Panacea Life Sciences Holdings in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Panacea Life Sciences Holdings' value of 4 is 20% below this benchmark. Historically, Panacea Life Sciences Holdings' own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Panacea Life Sciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Drug Manufacturers industry median of 5.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Piotroski F-Score is 4 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panacea Life Sciences Holdings Business Description

Address 5910 South University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.